Resurrection of sildenafil: potential for Huntington’s Disease, too?

The phosphodiesterase-5 inhibitor sildenafil was postulated to reduce the risk for Alzheimer’s Disease. Since preclinical data revealed beneficial effects in Huntington’s Disease (HD), we now for the first time investigated effects of sildenafil in HD patients using the database ENROLL-HD. We demons...

Descripción completa

Detalles Bibliográficos
Autores principales: Achenbach, Jannis, Faissner, Simon, Saft, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Short Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363275/
https://www.ncbi.nlm.nih.gov/pubmed/35633374
http://dx.doi.org/10.1007/s00415-022-11196-7
Descripción
Sumario:The phosphodiesterase-5 inhibitor sildenafil was postulated to reduce the risk for Alzheimer’s Disease. Since preclinical data revealed beneficial effects in Huntington’s Disease (HD), we now for the first time investigated effects of sildenafil in HD patients using the database ENROLL-HD. We demonstrate beneficial effects on motoric, functional and cognitive capacities in cross-sectional data. Those effects were not explained by underlying fundamental molecular genetic or demographic data. It remains unsolved, if effects are due to behavioral differences or due to direct dose-dependent neurobiological modulations.

Ejemplares similares